{
  "id": "58ec6eb5eda5a5767200000c",
  "type": "yesno",
  "question": "Is Enlimomab effective for stroke treatment?",
  "ideal_answer": "No. Anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in and may significantly worsen stroke outcome.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/9744839",
    "http://www.ncbi.nlm.nih.gov/pubmed/9693236",
    "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
    "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
    "http://www.ncbi.nlm.nih.gov/pubmed/19849665"
  ],
  "snippets": [
    {
      "text": "However, this treatment failed to show benefit in the Enlimomab Acute Stroke Trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9744839",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There was no increase in the frequency of adverse events with increasing doses of enlimomab.CONCLUSIONS: Doses of enlimomab between 140 and 480 mg administered over 5 days did not increase the risk of adverse events in patients with ischaemic or haemorrhagic stroke during an observation period of 30 +/- 10 days.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9693236",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND AND PURPOSE: Enlimomab, a murine monoclonal anti-human intercellular adhesion molecule (ICAM)-1 antibody, had a negative outcome in a multicenter acute-stroke trial. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These observations provide several possible mechanisms for central nervous system-related clinical deterioration that occurred when Enlimomab was given in acute ischemic stroke.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fewer patients had symptom-free recovery on enlimomab than placebo (p = 0.004), and more died (22.2 versus 16.2%). The negative effect of enlimomab was apparent on days 5, 30, and 90 of treatment (p = 0.005). There were significantly more adverse events with enlimomab treatment than placebo, primarily infections and fever. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients experiencing fever were more likely to have a poor outcome or die.The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The negative effect of enlimomab was apparent on days 5, 30, and 90 of treatment (p = 0.005).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients experiencing fever were more likely to have a poor outcome or die.<br><b>CONCLUSIONS</b>: The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Unfortunately, the case fatality rate in this trial was significantly higher in the enlimomab patient group than in the placebo group.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19849665",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND PURPOSE Enlimomab, a murine monoclonal anti-human intercellular adhesion molecule (ICAM)-1 antibody, had a negative outcome in a multicenter acute-stroke trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://meshb.nlm.nih.gov/record/ui?ui=D020521",
    "https://meshb.nlm.nih.gov/record/ui?ui=D016896",
    "http://www.biosemantics.org/jochem#4002166"
  ],
  "exact_answer": "Yes"
}